Key result
Daily administration of captopril for 3 weeks in mice with human lung cancer xenografts significantly reduced tumor growth by 58% (P<0.01) and lymph node metastasis by 50% (P=0.088).
Why the study?
Does captopril reduce tumor growth and metastasis in athymic mice with LNM35 human lung cell xenografts?
Population
Athymic mice injected with highly tumorigenic LNM35 human lung cells as xenografts
Comparison
Captopril 2.8 mg/mouse daily via intraperitoneal… vs null
Design
Preclinical
Follow-up
3 weeks
Authors
Loading...
Captopril shows anticancer activity in lung cancer xenografts; leaves open any role in human cancer prevention or therapy.
Does captopril reduce tumor growth and metastasis in athymic mice with LNM35 human lung cell xenografts?
Effect estimate: 58% reduction
p-value: p=< 0.01
Captopril significantly reduces tumor growth and induces apoptosis in a mouse xenograft model of human lung cancer, suggesting potential repurposing as an anticancer agent.
Attoub et al. (2008) studied Lung cancer. Captopril was evaluated on Tumor growth (58% reduction, p=< 0.01). Daily administration of captopril for 3 weeks in mice with human lung cancer xenografts significantly reduced tumor growth by 58% (P<0.01) and lymph node metastasis by 50% (P=0.088).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: